Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection. We investigated the real-world efficacy, changes in liver stiffness and noninvasive fibrosis markers, and the safety of DCV+ASV treatment in Korean patients. Methods: In total, 363 patients with chronic hepatitis C were treated with DCV+ASV between August 2015 and January 2017. Finally, we analyzed the data of 270 patients who were monitored for at least 12 weeks after the end of treatment. Results: The mean age was 60.7 years, and females predominated (60.4%). Most patients (64.8%) were treatment-naïve, and 56 patients (20.7%) had cirrhosis. Two hundred fifty-seven (95.2%) and 251 (93.0%) patients achieved end-of-treatment responses and sustained virological responses at 12 weeks posttreatment (SVR12), respectively. The SVR12 rates were higher in patients who were <65 years of age, males, without cirrhosis and had lower HCV RNA levels. All LS values and fibrosis-4 and aspartate aminotransferase-to-platelet ratio index values declined from baseline to the time of assessment of SVR12. Conclusions: The DCV+ASV therapy resulted in a high SVR12 and improved liver fibrosis; the treatment was well tolerated in patients with genotype 1b HCV infections.
Abstract
Background/Aims: The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection. We investigated the real-world efficacy, changes in liver stiffness and noninvasive fibrosis markers, and the safety of DCV+ASV treatment in Korean patients. Methods: In total, 363 patients with chronic hepatitis C were treated with DCV+ASV between August 2015 and January 2017. Finally, we analyzed the data of 270 patients who were monitored for at least 12 weeks after the end of treatment. Results: The mean age was 60.7 years, and females predominated (60.4%). Most patients (64.8%) were treatment-naïve, and 56 patients (20.7%) had cirrhosis. Two hundred fifty-seven (95.2%) and 251 (93.0%) patients achieved end-of-treatment responses and sustained virological responses at 12 weeks posttreatment (SVR12), respectively. The SVR12 rates were higher in patients who were <65 years of age, males, without cirrhosis and had lower HCV RNA levels. All LS values and fibrosis-4 and aspartate aminotransferase-to-platelet ratio index values declined from baseline to the time of assessment of SVR12. Conclusions: The DCV+ASV therapy resulted in a high SVR12 and improved liver fibrosis; the treatment was well tolerated in patients with genotype 1b HCV infections.
참고문헌 (37)
- Miyaki E, "Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients", Hepatol Res, 46, pp.758~764 (2016)[DOI]
- Ran Xu Zhu, "Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region", Gut and Liver, 10(3), pp.332~339 (2016), 거트앤리버 소화기연관학회협의회
- Kiyosawa K, "Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus", Hepatology, 12(4), pp.671~675 (1990)[DOI]
- Niederau C, "Prognosis of chronic hepatitis C: results of a large, prospective cohort study", Hepatology, 28, pp.1687~1695 (1998)[DOI]
- Gower E, "Global epidemiology and genotype distribution of the hepatitis C virus infection", J Hepatol, 61(1 Suppl), pp.S45~S57 (2014)[DOI]
- Kim BK, "Current status of and strategies for hepatitis C control in South Korea", Clin Mol Hepatol, 23, pp.212~218 (2017)[DOI]
- Gaetano JN, "Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir", Drug Healthc Patient Saf, 6, pp.37~45 (2014)
- Kanda T, "New antiviral therapies for chronic hepatitis C", Hepatol Int, 4, pp.548~561 (2010)[DOI]
- Gao M, "Antiviral activity and resistance of HCV NS5A replication complex inhibitors", Curr Opin Virol, 3, pp.514~520 (2013)[DOI]
- 조병욱, "Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study", Clinical and Molecular Hepatology, 23(1), pp.51~56 (2017), 대한간학회[DOI]
- Kao JH, "Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis", Liver Int, 36, pp.954~962 (2016)[DOI]
- McPhee F, "Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)", Antimicrob Agents Chemother, 56, pp.5387~5396 (2012)[DOI]
- Chayama K, "Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders", Hepatology, 55, pp.742~748 (2012)[DOI]
- Kumada H, "Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection", Hepatology, 59, pp.2083~2091 (2014)[DOI]
- Suzuki Y, "Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options", J Hepatol, 58, pp.655~662 (2013)[DOI]
- Manns M, "All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study", Lancet, 384, pp.1597~1605 (2014)[DOI]
- Muir AJ, "Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis", JAMA, 313, pp.1736~1744 (2015)[DOI]
- Asahina Y, "Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection", Hepatology, 52, pp.518~527 (2010)[DOI]
- Nishiguchi S, "Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis", Lancet, 357, pp.196~197 (2001)[DOI]
- Morgan RL, "Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies", Ann Intern Med, 158(5), pp.329~337 (2013)[DOI]
- Elsharkawy A, "Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon", J Gastroenterol Hepatol, 32, pp.1624~1630 (2017)[DOI]
- Everson GT, "Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection", Gastroenterology, 146, pp.420~429 (2014)[DOI]
- Kwo PY, "ACG clinical guideline: evaluation of abnormal liver chemistries", Am J Gastroenterol, 112, pp.18~35 (2017)[DOI]
- Ziol M, "Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C", Hepatology, 41, pp.48~54 (2005)[DOI]
- Adler M, "The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases", Hepatology, 47, pp.762~763 (2008)[DOI]
- Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
- Petersen JR, "Evaluation of the aspartate aminotransferase", platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C, 2014, pp.48, 370~376
- Chon YE, "The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B", J Clin Gastroenterol, 46, pp.518~525 (2012)[DOI]
- Seong MH, "Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study", J Med Virol, 85, pp.1724~1733 (2013)[DOI]
- Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines: management of hepatitis C", Clin Mol Hepatol, 20, pp.89~136 (2014)[DOI]
- Morio K, "Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virusinfected cirrhosis patients", J Gastroenterol Hepatol, 32, pp.645~650 (2017)[DOI]
- Suda G, "Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C", J Gastroenterol, 51, pp.733~740 (2016)[DOI]
- Moon C, "Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin", Dig Dis Sci, 60, pp.573~581 (2015)[DOI]
- Hye Won Lee, "Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response", Gut and Liver, 10(3), pp.429~436 (2016), 거트앤리버 소화기연관학회협의회
- Lens S, "Effects of all-oral antiviral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis", Gastroenterology, 153, pp.1273~1283 (2017)[DOI]
- Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C", Hepatology, 38, pp.518~526 (2003)
- Tada T, "Improvement of liver stiffness in patients with hepatitis C virus infection who received directacting antiviral therapy and achieved sustained virological response", J Gastroenterol Hepatol, 32, pp.1982~1988 (2017)[DOI]